First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
a study on Cancer, General Breast Cancer Solid Tumor PI3K Gene Mutation
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at Los Angeles 5368361, California 5332921 and other locations
- Dates
- study startedstudy ends around
- Principal Investigator
- by Aditya Bardia, MD, MPH

Description
Summary
OKI-219-101 is a Phase 1a/1b, open-label, multicenter, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and efficacy of OKI-219 as monotherapy and in combination with other anti-cancer drugs. Phase 1a (Part A) will investigate escalating doses of OKI-219 monotherapy, and Phase 1b will investigate OKI-219 (at a tolerated dose determined in Part A) in combination with fulvestrant (Part B), trastuzumab and tucatinib (Part C), atirmociclib (Part D), and ribociclib and fulvestrant (Part E). Participants will continue to receive study treatment until disease progression, intolerable toxicity, or other study treatment withdrawal criteria are met.
Official Title
PIKture-01: First-in-Human Study of the PI3KαH1047R Mutant-Selective Inhibitor OKI-219 as Monotherapy in Participants With Advanced Solid Tumors and as Part of Combination Therapy in Participants With Advanced Breast Cancer
Keywords
Advanced Cancer, Breast Cancer, Advanced Solid Tumors, PI3K Gene Mutation, PI3K, Solid Tumor, OKI-219, trastuzumab, fulvestrant, H1047r, ribociclib, atirmociclib, tucatinib, Breast Neoplasms
Eligibility
You can join if…
Open to people ages 18 years and up
- Participants with advanced solid tumors with documented evidence of a PI3KαH1047R mutation in tumor tissue and/or blood (ie, ctDNA).
- Eastern Cooperative Oncology Group (ECOG) Performance status score of to 1.
- Life expectancy > 12 weeks for Part A and > 6 months for Parts B, C, D, and E in the opinion of the Investigator.
- Adequate organ and bone marrow function
- Have adequate archival tumor tissue sample available or be approved by the Sponsor for enrollment if no tumor sample is available.
- At least 1 measurable lesion based on RECIST version 1.1.
Additional Cohort-specific key inclusion criteria:
Part A
- Participants with HR+/HER2- locally advanced, unresectable or metastatic breast cancer, must have received at least 1 prior line of hormonal therapy and at least 1 prior line of CDK4/6-inhibitor in the advanced or metastatic setting.
- Participants with HER2+ locally advanced, unresectable or metastatic breast cancer, must have received prior taxane, trastuzumab, pertuzumab, and tucatinib. Prior trastuzumab deruxtecan is allowed but not required.
- Participants with HER2-low breast cancer must have received prior trastuzumab deruxtecan.
- Participants with colorectal cancer must have KRAS wild-type disease.
Part B
- Participants with locally advanced, unresectable or metastatic HR+/HER2- breast cancer must have received at least 1 prior line of hormonal therapy in the advanced or metastatic setting and at least 1 prior CDK4/6-inhibitor.
- Participants with HER2-low breast cancer should have received prior trastuzumab deruxtecan
Part C ● Participants with HR±/HER2+ locally advanced, unresectable or metastatic breast cancer must have received prior taxane, trastuzumab, and pertuzumab unless unavailable in the region or contraindicated. Prior trastuzumab deruxtecan is allowed but not required.
Part D
● Participants must have HR+/HER2- locally advanced, unresectable or metastatic breast cancer
Part E ● Participants must have HR+/HER2- locally advanced, unresectable or metastatic breast cancer.
You CAN'T join if...
- Treatment with any investigational product or other anticancer therapy within 28 days or 5 half-lives, whichever is shorter, of the start of treatment
- Participants with a known KRAS mutation.
- Participants with a known deleterious mutation in phosphatase and tensin homolog (PTEN) or negative for PTEN protein expression by IHC.
- Major surgery or wide-field radiation within 28 days or limited field palliative radiation within 7 days prior to the first dose of study drug.
- Known active central nervous system metastasis, including leptomeningeal disease.
- Uncontrolled Type 1 or Type 2 diabetes as defined by HbA1C ≥ 8%.
- Concomitant active malignancy or previous malignancy within 2 years of the time of enrollment.
- Impaired cardiovascular function or clinically significant cardiovascular disease,
- History of symptomatic drug-induced pneumonitis.
- Participants with active HIV, Hepatitis B, and Hepatitis C viral infections
Additional Cohort-specific key exclusion criteria:
Part C:
- Grade 2 or higher diarrhea at study entry.
- History of chronic liver disease.
Part E:
● History of interstitial lung disease.
Locations
- UCLA Jonsson Comprehensive Cancer Center
accepting new patients
Los Angeles 5368361 California 5332921 90024 United States - Hoag - Huntington Beach
accepting new patients
Newport Beach 5376890 California 5332921 92663 United States
Lead Scientist at UCLA
- Aditya Bardia, MD, MPH
Professor, Medicine. Authored (or co-authored) 292 research publications
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- OnKure, Inc.
- Links
- Sign up for this study
- ID
- NCT06239467
- Phase
- Phase 1 research study
- Study Type
- Interventional
- Participants
- Expecting 200 study participants
- Last Updated
Please contact me about this study
We will not share your information with anyone other than the team in charge of this study, which might include an external sponsor. Providing your contact details does not obligate you to participate in the research.
Thank you!
The study team should get back to you in a few business days.